Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Taucher

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Travel Medicine and Infectious Disease|March 12, 2020
Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up studyChristian Taucher, Elizabeth D Barnett, Jakob P Cramer, et al.
Journal of Diabetes Science and Technology|May 31, 2026
Value and Sustainability of Semi-reusable Patch Pump Therapy in Routine Care: A Prospective Multicentre StudyJulia Mader, Julia Jantz, Christian Taucher, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Travel Medicine and Infectious Disease|March 18, 2018
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO<sup>®</sup>, JESPECT<sup>®</sup>) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 studyTomas Jelinek, Michael A Cromer, Jakob P Cramer, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
The Journal of Infection|June 19, 2022
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adultsRajeka Lazarus, Christian Taucher, Claire Brown, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Travel Medicine and Infectious Disease|March 12, 2020
Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up studyChristian Taucher, Elizabeth D Barnett, Jakob P Cramer, et al.
Journal of Diabetes Science and Technology|May 31, 2026
Value and Sustainability of Semi-reusable Patch Pump Therapy in Routine Care: A Prospective Multicentre StudyJulia Mader, Julia Jantz, Christian Taucher, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Microorganisms|April 27, 2024
Validation of a Human Challenge Model Using an LT-Expressing Enterotoxigenic <i>E. coli</i> Strain (LSN03-016011) and Characterization of Potential Amelioration of Disease by an Investigational Oral Vaccine Candidate (VLA1701)Kawsar R Talaat, Chad K Porter, Subhra Chakraborty, et al.
Travel Medicine and Infectious Disease|March 18, 2018
Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO<sup>®</sup>, JESPECT<sup>®</sup>) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 studyTomas Jelinek, Michael A Cromer, Jakob P Cramer, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
The Journal of Infection|June 19, 2022
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adultsRajeka Lazarus, Christian Taucher, Claire Brown, et al.
Pageof 2